Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ PASC 26% Improvement Relative Risk PASC (b) 25% c19early.org/f Sidky et al. SSRI for COVID-19 Prophylaxis Favors SSRI Favors control
Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19
Sidky et al., medRxiv, doi:10.1101/2022.11.09.22282142 (Preprint)
10 Nov 2022    Source   PDF   Share   Tweet
N3C retrospective 17,933 COVID-19 patients in the USA, showing lower risk of PASC for SSRIs with or without S1R agonist activity.
risk of PASC, 26.0% lower, RR 0.74, p < 0.001, treatment 2,021, control 14,584, S1R agonist SSRI.
risk of PASC, 25.0% lower, RR 0.75, p = 0.003, treatment 1,328, control 14,584, non-S1R agonist SSRI.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sidky et al., 10 Nov 2022, retrospective, placebo-controlled, multiple countries, preprint, 8 authors, study period 1 October, 2021 - 7 April, 2022.
Contact: hythem.sidky@nih.gov, david.sahner@nih.gov.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit